Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 9/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27375418 | 0.84 | DPP4 (0.41) | F2PLATPRSS1BIRC2XIAP | |
| SCHEMBL21307631 | 0.82 | DPP4 (0.39) | F2PLATPRSS1BIRC2XIAP | |
| SCHEMBL18754852 | 0.80 | DPP4 (0.43) | BIRC2DPP4 | |
| SCHEMBL27437988 | 0.78 | DPP4 (0.41) | F2PLATPRSS1BIRC2DPP4 | |
| SCHEMBL17069040 | 0.76 | P2RX7 (0.50) | F2NPSR1DPP4POLBTSHR | |
| SCHEMBL27438305 | 0.74 | XIAP (0.59) | BIRC2XIAPBIRC3 | |
| SCHEMBL23975499 | 0.74 | TP53 (0.40) | DPP4 | |
| SCHEMBL23975465 | 0.74 | TP53 (0.40) | DPP4 | |
| SCHEMBL22402905 | 0.73 | BIRC2 (0.43) | F2PLATPRSS1BIRC2FKBP5 | |
| SCHEMBL26461271 | 0.73 | BIRC2 (0.43) | F2PLATPRSS1BIRC2FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | F2 4769/4885PLAT 4565/4885PRSS1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.